Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday, including sales of the cystic fibrosis drug Orkambi in the range of $1.1 to $1.3 billion. At the midpoint of Vertex’s 2017 guidance, Orkambi sales will grow 23% compared to 2016 but that’s still $200 million-plus short of the current Street consensus.